Design
This is a randomized controlled trial. The protocol was drawn up in accordance with the Consolidated Standards of Reporting Trials guidelines and the Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines (STRICTA).1920 The protocol has been approved by the Institutional Review Board of the Hospital of Chengdu University of Traditional Chinese Medicine (approved number: 2020KL-007) and registered at Chinese Clinical Trial Registry (registration number: ChiCTR2000040930, protocol version number: V1.0).
This study period last for 16 weeks, which included a 2-week baseline period, a 2-week intervention period, and a 12-week following period. A total of 86 patients with NP will be randomly assigned to the two acupuncture groups with a 1:1 ratio. 20 patients in each group will be randomly selected to undertake fMRI scans. Clinical outcome evaluation and fMRI scans will be conducted at baseline and after treatment. The study procedure is outlined in Fig. 1 and Table 1.
Table 1
Study schedule for data collection.
Period
|
Baseline
|
Treatment
|
Follow-up
|
Assessment
|
|
1
|
|
2
|
3
|
4
|
Time (week)
|
0
|
2
|
3
|
4
|
8
|
16
|
Pick-up information
|
|
Inclusion/exclusion criteria
|
√
|
|
|
|
|
|
|
|
|
|
Informed consent
|
√
|
|
|
|
|
|
|
|
|
|
Vital signs
|
√
|
|
|
|
|
|
|
|
|
|
Medical history
|
√
|
|
|
|
|
|
|
|
|
|
Physical examination
|
√
|
|
|
|
|
|
|
√
|
|
|
Acupuncture intervention
|
Group A (n = 43)
|
|
|
√
|
√
|
√
|
√
|
√
|
√
|
|
|
Group B (n = 43)
|
|
|
√
|
√
|
√
|
√
|
√
|
√
|
|
|
Clinical assessment
|
VAS
|
√
|
√
|
|
|
|
|
|
√
|
√
|
√
|
NDI
|
|
√
|
|
|
|
|
|
√
|
√
|
√
|
ROM
|
√
|
√
|
|
|
|
|
|
√
|
√
|
√
|
PPT
|
|
√
|
|
|
|
|
|
√
|
√
|
√
|
SF-36
|
|
√
|
|
|
|
|
|
√
|
√
|
√
|
MSUS
|
|
√
|
|
|
|
|
|
√
|
|
|
SAS and SDS
|
|
√
|
|
|
|
|
|
√
|
√
|
√
|
fMRI (n = 40)
|
|
√
|
|
|
|
|
|
√
|
|
|
Laboratory test
|
|
√
|
|
|
|
|
|
√
|
|
|
Adverse event
|
|
|
|
|
|
|
|
√
|
|
|
This is a randomized controlled trial of neuroimaging including a 2-week baseline period, a 2-week treatment period, and a 12-week follow-up period. At baseline, participants will be screened based on inclusion and exclusion criteria; eligible individuals will then sign informed consent and undergo a physical examination. After randomized into 2 groups, 6 acupuncture treatments will be performed for 2 weeks. Clinical data will be evaluated at baseline, after treatment ends, and at 4 and 12 weeks after completion, fMRI scans will be performed before the first and sixth acupunctures. After the treatment, laboratory tests will be performed, including routine blood test, C-reactive protein, and erythrocyte sedimentation tests. Adverse events will be recorded in the CRF at any time during treatment. |
fMRI functional magnetic resonance imaging, VAS Visual Analogue Acales, NDI Neck Disability Index, ROM Cervical Range of Motion, PPT Pressure Pain Threshords, MSUS musculoskeletal ultrasound, SF-36 short-form 36-item Health Survey, SAS Self-Rating Anxiety Scale, SDS Self-Rating Depression, CRF case report form |
Participants
Recruitment procedures
Patients will be recruited at the outpatient of the Hospital of Chengdu University of Traditional Chinese Medicine (TCM) and Sichuan Integrated Medicine Hospital. In addition, patients will also be recruited from the community and campus of Chengdu University of TCM through advertising (posting notices, distributing leaflets, web publishing). Patients who agree to participate in this study will be diagnosed by an orthopedic specialist. The eligible patients will be screened by the research assistant based on the inclusion and exclusion criteria.
Inclusion criteria
Participants who match the inclusion criteria will be included: 1) those with NP as the main complaint and a visual analog scale (VAS) score of pain severity exceeding 4 points but less than 10 points (range 0–10 points); and 2) for a duration of ≤ 3 months; and 3) aged 18–60 years; and 4) agreeing to sign informed consent.
Exclusion criteria
Participants with any of the following conditions will be excluded: 1) they are pregnant or lactating women; or 2) they have any organic or metabolic diseases of the digestive, hematopoietic, endocrine, or immune systems, or other severe primary diseases; or 3) they have local skin damage or severe skin diseases that affect acupuncture manipulation; or 4) they combine with mental or neurological diseases; or 5) they have received acupuncture for NP within one month; or 6) they have MRI contraindications, such as heart pacemaker, metallic foreign bodies, or severe claustrophobia, etc.; or 7) they are participating in other clinical trials.
Sample size
This study aims to compare the difference of the clinical efficacy of two acupuncture prescriptions (Group A and Group B). According to the results of the pilot study, the average reduction of VAS score in Group A was 2.86 ± 0.99, and the average reduction of VAS score in Group B was 2.14 ± 0.99. According to the formula, , with α = 0.05 (both sides) and 1-β = 0.80.21 The sample size of each group was calculated to be 34, considering a 20% dropout rate, the final sample size was set to 43 per group, making the total of 86 in this study.
There is no widely accepted method for sample size calculation in neuroimaging study. Referring to the previous study,22 15 participants in each group is the smallest size in neuroimaging studies. Considering a 20% dropout rate and the unavailability of data due to various reasons, this study will randomly select 20 patients from each group for fMRI scans.
Randomization and blinding
Randomization will be carried out in two steps: 1) an independent, blinded statistician will generate a random allocation sequence using SPSS 26.0 (IBM, Chicago, IL, USA). The 86 patients will be randomly assigned into Group A and Group B at a ratio of 1:1; 2) 20 patients from each group will be randomly selected for fMRI. Allocation concealment will be achieved by sequentially numbered, opaque, sealed envelopes.
In this study, the patients, outcome assessors and statistical analysts will be blinded. The patients will be treated at the separate rooms to reduce communication. However, due to the particularity of acupuncture manipulation, blinding operator cannot be achieved.
Interventions
Patients in Group A will receive acupuncture at three acupoints (Lieque (LU7), Chize (LU5) and neck tenderness point on the affected side) (Fig. 2A). The acupoints of Group B (control group) will receive acupuncture at three acupoints (Shaohai (HT3), Lingdao (HT4) and neck tenderness point on the affected side) (Fig. 2B). Tenderness points will be detected using a PX25 hand-held pressure pain tester (Wagner FPX™ 25).
The acupuncture manipulations are as follows: disposable sterile filiform needles (0.30 × 40 mm, Huatuo Medical Instrument Co.,Ltd., China) will be inserted into acupoints at a depth of 20–30 mm after skin disinfection, and the Deqi sensation (a sensation of acid distension or numbness, or other acupuncture sensation) will be achieved.23 Then, HANS-200A acupoint nerve stimulator (Nanjing Jisheng Medical Technology Company, Nanjing city, China) will connect LU7 and LU5 of Group A or HT3 and HT4 of Group B respectively in the two groups for 30 minutes with dilatational waves (2-100 Hz, 1 mA). Patients will receive a total of 6 sessions of acupuncture in two weeks with 3 sessions per week.
Acupuncture treatment will be performed by acupuncturists who have held a practitioner license for more than 3 years.
Concomitant medications
Patients will be instructed not to take any other analgesic medications for NP during this study. In cases of severe NP, ibuprofen (300 mg per capsule with sustained release) will be allowed as rescue medication and should be recorded on the case report form (CRF).
Outcome measurements
The measurements will be conducted by independent assessors who have been trained prior to the study. The primary outcome is the change of VAS scores for pain severity from baseline to 2 weeks. VAS scores range from 0 to 10, with 0 indicating no pain and 10 indicating pain is unbearable. The secondary outcome measurements including: Neck Disability Index (NDI), Short-Form 36-Item Health Survey (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Range of Motion (ROM) and Pressure Pain Threshold (PPT) will be evaluated at baseline, after treatment, and at 4 and 12 weeks after the end of treatment. In addition, we will perform musculoskeletal ultrasound (MSUS) before and after treatment. Among them, NDI is the most widely used clinical tool for self-assessment of disability caused by NP.24 The SAS and SDS are the commonly used psychometric tools to measure the severity of anxiety and depression.25 26 SF-36 is a general health-based survey of quality of life, which can be self-administered by the patient with reliability.27 ROM is one of the quantitative outcomes assessing the extent and degree of joint motor impairment. The changes of the tenderness threshold can quantitatively reflect the improvement of the pain severity.28 Meanwhile, MSUS is an important means for clinical diagnosis of rehabilitation medicine, tracking disease progression and assessing curative effect.29
Patient safety
Adverse events during treatment will be reported in the CRF. The record should include the time, reason, clinical symptoms, and signs of the adverse event, as well as the corresponding emergency treatment plan.
MRI data acquisition
The resting-state fMRI (RS-fMRI) will be performed at the baseline and the end of treatment, respectively. Patients will be asked to do not drink tea, coffee, or alcohol, avoid strenuous exercise, and ensure adequate sleep before the scan.
Patients will undergo RS-fMRI scan with a 3.0T MR scanners (Siemens 3T Tim trio, Erlangen, Germany) at the West China Hospital of Sichuan University. Patients will be asked to stay awake and to keep their heads still during the scan, with their eyes closed and ears plugged. Scans will be performed with the following procedures: localizer, three-dimensional T1-weighted imaging (3D-T1WI), blood oxygenation level-dependent fMRI (BOLD-fMRI) and diffusion tensor imaging (DTI) sequence. The 3D-T1WI scanning parameters will be as follows: repetition time (TR) = 6.008 ms, echo time (TE) = 1.7 ms, data matrix = 256 × 256, field of view (FOV) = 256 × 256 mm2. The BOLD-fMRI scanning parameters will be as follows: 31 contiguous slices with a slice thickness of 5 mm, TR = 2000 ms, TE = 30 ms,FOV = 240 × 240 mm2, Matrix = 64 × 64, flip angle (FA) = 90°, total volumes = 240. The DTI data will be acquired using a single-shot echo planar image sequence with the following parameters: FOV = 256 × 256 mm2, TR = 8500 ms, matrix = 128 × 128, slice thickness = 2 mm with no gap. Two diffusion-weighted sequences were acquired using gradient values b = 1000 s/mm2 and b = 0 s/mm2 with the diffusion-sensitizing gradients applied in 64 non-collinear directions.
Statistical analysis
Clinical data analysis
The comprehensive effectiveness analysis will use the per protocol set (PPS) and the full analysis set (FAS). The FAS population will be used as the primary population for all efficacy analyses. The safety set (SS) included all subjects who received at least one treatment after randomization. When the results of PPS analysis and FAS analysis are inconsistent, PPS and FAS are discussed separately to find out the reasons for the inconsistency. Missing data will be handled using the last-observation-carried-forward (LOCF) method.
Statistical analysis will be conducted using SPSS 26.0 (IBM, Chicago, IL, USA) statistical software. P < 0.05 (two-sided) is considered statistically significant. Quantitative data are described with mean ± standard deviation (SD). Qualitative data are described with frequency and percentage (N, %). Student’s t-test and chi-square test will be used to compare the differences between groups at baseline. The primary outcome will be carried out with a paired samples t-test, and the secondary outcome will be compared at four timepoints using the repeated measures ANOVA. Clinical data on skewed distribution will be compared using a non-parametric test.
MRI data analysis
The fMRI data preprocessing and comparison will be performed using SPM12 software (http://www.fil.ion.ucl.ac.uk/spm/) based on MATLAB 2018a (Mathworks, Inc., USA). The steps including: format conversion, slice timing correction, head motion correction, spatial standardization, linear trend removal, spatial smoothing, and band-pass filtering. After pre-processing, the amplitude of low frequency fluctuation and regional homogeneity will be calculated to reflect the local cerebral functional activity, and the seeds-based functional connection analysis will be performed to reflect the functional integration of the brain. ANOVA will be used for comparisons between the two groups, with multiple comparison corrections.
Furthermore, the Pearson correlation analysis will be conducted to assess the associations between the changes of fMRI and the improvement of clinical symptoms.